Typhoid Fever Vaccines Market Report Scope & Overview:

The Typhoid Fever Vaccines Market was valued at USD 0.51 Billion in 2025 and is expected to reach USD 1.25 Billion by 2035, growing at a CAGR of 9.36% from 2026-2035.

The Typhoid Fever Vaccines Market will see traction due to WHO and Gavi-backed routine rollout of typhoid conjugate vaccines, rising antimicrobial resistance in Salmonella Typhi, and large catch-up campaigns across South Asia and Africa. Conjugate vaccines are replacing older polysaccharide products because they protect infants from six months of age with a single dose. WHO prequalification of multiple conjugate suppliers has widened supply and pushed public tender prices below USD 2 per dose. Recovering international travel is also lifting private demand for injectable and oral vaccines among travelers visiting endemic regions. Pharmacy-based vaccination is further widening convenient access for these travelers.

⮞In October 2025, a typhoid conjugate vaccine campaign covered 33 Rohingya camps in Cox’s Bazar, Bangladesh, protecting children aged nine months to 15 years. The campaign reflects growing use of TCVs in humanitarian settings where crowding and poor sanitation raise typhoid outbreak risk.

U.S. Typhoid Fever Vaccines Market Outlook

The U.S. Typhoid Fever Vaccines Market was valued at USD 56.24 Million in 2025 and is expected to reach USD 104.83 Million by 2035, growing at a CAGR of 6.42% from 2026-2035.

The U.S. Typhoid Fever Vaccines Market is expanding owing to steady demand from international travelers, military personnel, and laboratory workers exposed to Salmonella Typhi. Most U.S. typhoid cases are linked to travel to South Asia, Africa, and Latin America, prompting CDC recommendations for vaccination before visiting endemic regions. Two vaccines are available in the country: the injectable Vi polysaccharide vaccine Typhim Vi and the oral live attenuated vaccine Vivotif. Travel clinics, retail pharmacies, and hospital travel medicine services administer most doses. Rising outbound travel and growing concern about drug-resistant typhoid continue to support demand. Pharmacy vaccination programs are also making pre-travel protection easier to access nationwide.

⮞In 2023, Bavarian Nordic completed its acquisition of Emergent BioSolutions’ travel health business, including Vivotif, the oral typhoid vaccine licensed in the United States. The deal strengthened Bavarian Nordic’s travel vaccine portfolio and expanded its commercial presence among U.S. travel clinics and pharmacies.

By Vaccine Type, Vi Polysaccharide Leads, While Conjugates Grow Fastest

The Vi polysaccharide segment dominated the Typhoid Fever Vaccines Market in 2025, as these vaccines have been used for decades in national programs, private clinics, and travel medicine. Products such as Sanofi’s Typhim Vi and several Asian-made Vi-PS vaccines offer a single injection, rapid protection, and established regulatory approvals worldwide. Many existing procurement contracts and private-sector channels still rely on these vaccines. However, Vi-PS vaccines are not effective in children under two years and provide shorter protection, which is gradually shifting public health programs toward newer conjugate vaccines over the forecast period. Even so, Vi-PS remains widely used for adult travelers.

Conjugate vaccines are the fastest-growing type, supported by WHO’s recommendation of typhoid conjugate vaccines for routine use from six months of age. Linking the Vi antigen to a carrier protein produces stronger, longer-lasting immunity in infants and young children. Typbar-TCV from Bharat Biotech, TyphiBEV from Biological E, SKYTyphoid from SK bioscience, and ZyVac TCV from Zydus hold WHO prequalification, widening supply for Gavi and UNICEF tenders. Large routine introductions and outbreak campaigns in Pakistan, Bangladesh, Nepal, and African countries continue to drive strong conjugate vaccine demand. New supplier entries and lower prices are also helping more countries afford routine introduction.

⮞In August 2026, the World Health Organization prequalified EuBiologics’ EuTYPH-C injectable typhoid conjugate vaccine in a multidose presentation, adding another supplier to the internationally prequalified TCV portfolio and expanding potential procurement options for national immunization programs and international vaccine buyers.

By Age Group, 6 to 15 Years Lead, While Infants Grow Fastest

The 6 to 15 years age group drove the Typhoid Fever Vaccines Market in 2025 due to the large burden of typhoid fever in endemic countries borne by school-aged children. In Pakistan, Bangladesh, Nepal, Zimbabwe, and Liberia, mass campaigns to reduce transmission have targeted children up to 15 years old in short periods, delivering millions of vaccine doses, thus generating high procurement volumes. School-based vaccination makes it easy to reach this age group. Emergence of drug-resistant typhoid fever in children has compelled authorities in several countries to immunize them with TCVs. Demand from this age group will continue from follow-up campaigns in the newly endemic countries.

Infants represents the fastest-growing segment, as many countries include one dose of a TCV in the immunization schedule for infants. WHO guidelines recommend TCV vaccination starting from the age of six months, typically combined with measles-containing vaccines at the age of nine months. Gavi support helps countries introduce TCVs through routine vaccination, thus ensuring steady and predictable demand per birth cohort. Conjugate vaccines induce immune responses in infants while polysaccharide vaccines fail to do so. This segment is projected to experience fast growth as more countries conduct catch-up campaigns and switch to routine infant vaccination.

⮞In July 2026, Bangladesh announced that typhoid conjugate vaccination would enter its routine Expanded Programme on Immunization from August, with a single dose scheduled for children aged 15 months. The decision creates a recurring infant and toddler vaccination channel beyond one-time catch-up campaigns.

By End User, Public Programs Lead, While Travel Clinics Grow Fastest

The public health and government programs segment dominated the Typhoid Fever Vaccines Market in 2025, as national immunization programs in endemic countries buy most typhoid vaccine doses through Gavi, UNICEF, and government tenders. Gavi-supported introductions and campaigns in Asia and Africa have delivered tens of millions of conjugate doses in recent years. Bulk procurement at low prices below USD 2 per dose creates high volumes but lower margins for manufacturers. Governments facing drug-resistant typhoid outbreaks, such as Pakistan and Bangladesh, have launched large campaigns that continue to support this segment’s leading share. Humanitarian campaigns in refugee settings add further volume.

Travel and retail clinics and pharmacies are the fastest-growing end user segment, driven by recovering international travel to South Asia, Africa, and Latin America. Travel health guidelines in the United States, Europe, and other high-income countries recommend typhoid vaccination before visiting endemic regions. Travel clinics and pharmacies offer injectable Vi-PS vaccines and oral Ty21a capsules, often priced well above public sector levels. Growing awareness of extensively drug-resistant typhoid among travelers and increasing pharmacy-based vaccination services are expanding access. Rising migration and visiting-friends-and-relatives travel are also expected to support strong growth. Large pharmacy chains are also steadily expanding their travel vaccine services.

⮞In July 2025, Kenya conducted a nationwide integrated vaccination campaign delivering typhoid conjugate vaccine to approximately 16.1 million children across all 47 counties. The campaign demonstrated the operational scale of government-led procurement and delivery of TCVs in high-burden settings.

Regional Analysis

North America Typhoid Fever Vaccines Market Insights

North America represented about 12.84% of the Typhoid Fever Vaccines Market in 2025, supported by strong demand from travelers, effective CDC travel health advisory, and wide distribution via travel clinics and pharmacies. The US is the largest economy within the region, with the sales of Sanofi's Typhim Vi and Bavarian Nordic's Vivotif for travelers, military personnel, and lab workers. In the US, most of the typhoid fever infections are associated with travel to endemic regions, mainly South Asia. Reports of extensively drug-resistant typhoid in travelers has brought attention among clinicians to vaccinate before travel. Pharmacies and travel clinics are making the pre-travel vaccines easier for travelers.

In Canada, the market remains stable due to the public health travel advisory programs and pharmacist-vaccination in various provinces. The presence of many immigrants from South Asia and Africa who travel to meet family and friends makes a good candidate group for vaccination. In Mexico, the market remains small as vaccination continues to be used in higher-risk scenarios in the presence of typhoid fever as a public health threat. The recovery of outbound travel, expanded vaccination services at pharmacies, and increasing awareness about travel vaccines is expected to boost steady growth. Currently, there is no conjugated vaccine for use in North America.

⮞In July 2026, the Public Health Agency of Canada updated its Canadian Immunization Guide for travellers, outlining typhoid vaccination recommendations for people visiting South Asia and identifying circumstances requiring individualized risk assessment. The guidance supports pre-travel consultation and vaccine access through Canadian healthcare providers and travel clinics.

Europe Typhoid Fever Vaccines Market Insights

Europe is a notable regional travel health market and features significant contributions from the UK, Germany, France, Italy, and Spain—regions where many travelers annually visit endemic areas. National bodies for travel health including UK Health Security Agency, recommend typhoid vaccine in South Asia, Africa, and Latin America. The market is led by Vi polysaccharide and oral Ty21a vaccines from companies including Sanofi, GSK, and Bavarian Nordic. The majority of vaccinations are carried out by travel clinics, general practitioner and pharmacies. The increased number of reports of drug-resistant typhoid cases among travelers increases awareness among tourists and clinicians, while pharmacy travel health services increase the number of countries served.

The UK leads the regional market owing to its significant ties with South Asia, having a considerable number of visiting‑friends-and-relatives travelers, as well as the presence of good NHS travel health service and a developed network of private travel health clinics. Germany and France have strong demand through high level of outbound travel and travel medicine centers, respectively. Italy and Spain have stable demand as a result of tourist traffic and migration-related travel. The EMA and national regulatory bodies have up-to-date labels for currently available vaccines. However, the absence of a conjugated vaccine for routine administration in almost all European countries and budget pressure in publicly funded healthcare systems hinder the market development.

⮞In July 2026, the UK Health Security Agency published provisional travel-associated infection data reporting 287 enteric fever cases across England, Wales and Northern Ireland during January–June. The update reinforced the continuing public-health relevance of imported typhoid and paratyphoid infections among international travellers.

Asia-Pacific Typhoid Fever Vaccines Market Insights

Asia-Pacific is the largest regional market and is anticipated to record a CAGR of around 9.72% during the forecast period from 2026 to 2035, driven by its high typhoid burden, drug-resistant outbreaks, and large conjugate vaccine campaigns. India is the largest market in the region, supported by a strong domestic manufacturing base, including Bharat Biotech, Biological E, Zydus, and Serum Institute of India. Several states have introduced typhoid conjugate vaccines, while Indian manufacturers supply large volumes to Gavi and UNICEF, making the country central to global typhoid vaccine supply and innovation. New domestic capacity is further strengthening India’s export position.

Pakistan and Bangladesh are key growth markets, driven by nationwide conjugate vaccine campaigns against extensively drug-resistant typhoid. Bangladesh launched a nationwide TCV drive in 2025 targeting children aged nine months to 15 years with United Nations support. Nepal has also introduced TCVs into routine immunization. China supports demand through domestic Vi polysaccharide vaccines produced by China National Biotec Group. South Korea strengthens regional supply through SK bioscience and EuBiologics, while Indonesia’s PT Bio Farma serves domestic and export markets. Continued campaigns and routine introductions are expected to sustain strong regional growth. Local manufacturing also supports faster supply to national programs.

⮞In May 2025, India's Central Drugs Standard Control Organization listed approval for a clinical trial of Biological E. Limited's bivalent typhoid and paratyphoid A conjugate vaccine. The regulatory milestone advanced development of a candidate designed to address both causes of enteric fever and broaden future vaccine options.

MEA & Latin America Typhoid Fever Vaccines Market Insights

Middle East & Africa (MEA) is characterized by a rapid increase due to the Gavi-assisted introduction of typhoid conjugate vaccines in sub-Saharan Africa along with investments in regional vaccine manufacture. Zimbabwe, Liberia, Malawi and other nations have carried out successful campaigns of introducing the typhoid conjugate vaccine and added the vaccine into the immunization schedule. Projects that increase local vaccine production and fill-finish capacity are supported by the African Vaccine Manufacturing Accelerator. The increased demand is driven by Gulf Cooperation Council due to travel and labor migrants as well as Hajj vaccination demands. Weak surveillance, cold chain issues and small public health budget present challenges for many countries in Africa. Sustaining vaccine introduction requires ongoing donor support.

Latin America presents a moderate market due to constant growth, which is caused by large population and immunization programs of the country. The problem with typhoid is its endemic status in some part of the region associated with poor sanitation and water safety. Demand drivers in Mexico, Argentina, Colombia involve private travel clinics and vaccination of specific population groups. Historical studies of the oral Ty21a vaccines use in travelers were conducted in Chile. Incidence of typhoid in the region is lower compared to Asia and Africa due to limited government funding of conjugate vaccines. Travel clinics serve as a key vaccination channel.

⮞In November 2025, Niger conducted a typhoid conjugate vaccination campaign alongside a preventive meningococcal vaccination initiative, targeting populations aged 1–19 years. The integrated campaign demonstrated how coordinated immunization delivery can expand access to typhoid prevention across African public-health systems.

Market Dynamics

Growth Drivers: Gavi-Backed TCV Rollout and Rising Drug Resistance

Growth in the Typhoid Fever Vaccines Market is primarily attributed to the WHO and Gavi-backed rollout of typhoid conjugate vaccines in endemic countries. WHO recommends TCVs for routine use from six months of age and for catch-up campaigns in children up to 15 years. Gavi funding has helped countries such as Pakistan, Bangladesh, Nepal, Liberia, Zimbabwe, and Malawi introduce conjugate vaccines through campaigns and routine programs. WHO prequalification of four conjugate vaccines has increased supply security and lowered prices, making large-scale public procurement more affordable for governments and donors. Growing multi-year procurement agreements also give manufacturers greater demand visibility and planning certainty.

The rise of antimicrobial-resistant Salmonella Typhi is further reinforcing market growth. Extensively drug-resistant typhoid, first identified in Pakistan’s Sindh province in 2016, has spread across South Asia and been reported among travelers worldwide. Resistance to ceftriaxone and other last-line antibiotics is narrowing treatment options and increasing hospitalization costs. Health authorities, including the CDC and WHO, identify vaccination as one of the most effective tools to prevent resistant infections. Typhoid still causes millions of cases and tens of thousands of deaths each year, mostly among children in Asia and Africa. This persistent burden keeps typhoid vaccination high on global health agendas.

⮞In September 2026, the U.S. Centers for Disease Control and Prevention published its 2024 national typhoid and paratyphoid surveillance summary, documenting 383 reported Salmonella Typhi cases across 35 jurisdictions. The report provides updated evidence for prevention efforts amid travel-associated infections and antimicrobial resistance concerns.

Restraints: Weak Surveillance and Funding Pressure

Weak disease surveillance remains a key factor limiting market growth. Many endemic countries rely on clinical diagnosis without laboratory confirmation, and blood culture testing is often unavailable in rural areas. As a result, the true burden of typhoid is frequently underestimated, making it difficult for health ministries to justify spending on new vaccines. Without strong local data, some countries delay decisions to introduce conjugate vaccines into routine programs. Limited laboratory capacity and poor reporting systems also make it harder to track outbreaks, measure vaccine impact, and plan targeted catch-up campaigns effectively. New WHO surveillance standards may gradually address these gaps.

Funding pressure on donors and governments is another limiting factor, as Gavi seeks new financing for its 2026–2030 strategy while many high-income donors face tight budgets. Middle-income countries transitioning out of Gavi support must fund vaccines themselves, often while managing high public debt. Funding shortfalls could slow new introductions or reduce the size of catch-up campaigns. In addition, cold-chain and energy gaps in rural Africa limit vaccine storage and delivery. Supply constraints for Vi polysaccharide bulk antigen and competing health priorities can further delay broader typhoid vaccination in several endemic regions. These factors may slow near-term growth in some markets.

Opportunities: Combination Vaccines and Regional Manufacturing

The development of combination and multi-antigen vaccines creates a significant opportunity for manufacturers, as paratyphoid fever is rising in parts of South Asia and is not covered by current typhoid vaccines. Serum Institute of India received clearance in 2025 to begin Phase II/III testing of its bivalent typhoid-paratyphoid A conjugate vaccine, while GSK and academic groups are developing other multi-antigen candidates. Combination vaccines could simplify immunization schedules and procurement for national programs. Companies that secure WHO prequalification for next-generation vaccines can capture long-term supply contracts with Gavi and UNICEF. Strong clinical data will be critical to gaining regulatory approval and program adoption.

At the same time, the expansion of regional vaccine manufacturing provides a major growth opportunity. The African Vaccine Manufacturing Accelerator is supporting new production and fill-finish facilities in countries such as Senegal, South Africa, and Kenya, which could reduce supply risks and delivery times. Technology transfer partnerships between Asian manufacturers and African producers can speed local typhoid vaccine production. Growing private-sector demand from travelers and middle-income consumers also creates opportunities for higher-value products. Thermostable formulations that reduce cold-chain requirements could further expand access in remote and resource-limited areas. Such innovations could also reduce vaccine wastage and lower delivery costs for health programs.

⮞In October 2025, the New England Journal of Medicine published clinical-trial findings for CVD 1902, an investigational oral live-attenuated vaccine against Salmonella Paratyphi A. The results support continued research into paratyphoid prevention, an unmet need that could complement existing typhoid-vaccine strategies if further development establishes safety and efficacy.

Typhoid Fever Vaccines Market Key Players

• Bharat Biotech International Limited

• Biological E. Limited

• SK bioscience Co., Ltd.

• Zydus Lifesciences Ltd.

• Sanofi S.A.

• Bavarian Nordic A/S

• Serum Institute of India Pvt. Ltd.

• PT Bio Farma (Persero)

• EuBiologics Co., Ltd.

• Bio-Med Pvt. Ltd.

• Incepta Pharmaceuticals Ltd.

Typhoid Fever Vaccines Market Report Scope: